Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Inhibition of Prohormone Convertases PC1/3 and PC2 by 2,5-Dideoxystreptamine Derivatives

Mirella Vivoli, Thomas R. Caulfield, Karina Martínez-Mayorga, Alan T. Johnson, Guan-Sheng Jiao and Iris Lindberg
Molecular Pharmacology March 2012, 81 (3) 440-454; DOI: https://doi.org/10.1124/mol.111.077040
Mirella Vivoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas R. Caulfield
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karina Martínez-Mayorga
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan T. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guan-Sheng Jiao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iris Lindberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The prohormone convertases PC1/3 and PC2 are eukaryotic serine proteases involved in the proteolytic maturation of peptide hormone precursors and are implicated in a variety of pathological conditions, including obesity, diabetes, and neurodegenerative diseases. In this work, we screened 45 compounds obtained by derivatization of a 2,5-dideoxystreptamine scaffold with guanidinyl and aryl substitutions for convertase inhibition. We identified four promising PC1/3 competitive inhibitors and three PC2 inhibitors that exhibited various inhibition mechanisms (competitive, noncompetitive, and mixed), with sub- and low micromolar inhibitory potency against a fluorogenic substrate. Low micromolar concentrations of certain compounds blocked the processing of the physiological substrate proglucagon. The best PC2 inhibitor effectively inhibited glucagon synthesis, a known PC2-mediated process, in a pancreatic cell line; no cytotoxicity was observed. We also identified compounds that were able to stimulate both 87 kDa PC1/3 and PC2 activity, behavior related to the presence of aryl groups on the dideoxystreptamine scaffold. By contrast, inhibitory activity was associated with the presence of guanidinyl groups. Molecular modeling revealed interactions of the PC1/3 inhibitors with the active site that suggest structural modifications to further enhance potency. In support of kinetic data suggesting that PC2 inhibition probably occurs via an allosteric mechanism, we identified several possible allosteric binding sites using computational searches. It is noteworthy that one compound was found to both inhibit PC2 and stimulate PC1/3. Because glucagon acts in functional opposition to insulin in blood glucose homeostasis, blocking glucagon formation and enhancing proinsulin cleavage with a single compound could represent an attractive therapeutic approach in diabetes.

Footnotes

  • This work was supported in part by a grant from the National Institutes of Health National Institute on Drug Abuse [Grant DA050854] (to I.L.); by the State of Florida Executive Officer of the Governor's Office of Tourism, Trade and Economic Development (to K.M-M.); and by the U.S. Department of Defense, U.S. Army Medical Research and Materiel Command [Contract V549P-6073] (to A.J. and G.-S.J.), [Grant OT07-050] (to K.M.-M.).

  • G.-S.J. is co-corresponding author regarding the inhibitor chemistry (gjiao{at}pantherabio.com).

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

    http://dx.doi.org/10.1124/mol.111.077040.

  • ABBREVIATIONS:

    PC
    prohormone convertase
    166369
    5-(2,4-diguanidino-phenoxy)-2,4-diguanidino-cyclohexyl (4-octylphenyl)carbamate
    166369a
    N,N′-di-tert-butoxycarbonyl-N″-{4-[2,4-di-(di-tert-butoxycarbonyl-guanidino)-phenoxy]-5-[di-(tert-butoxycarbonyl)-guanidino]-2-hydroxycyclohexyl}-guanidine
    166550
    N-[2,4-bis(4-guanidino-phenoxy)-5-(4-guanidino-phenylamino)-cyclohexyl]-guanidine
    166631
    N-[5-guanidino-2,4-bis-(4-guanidino-phenoxy)-cyclohexyl]-guanidine
    166646
    5-(2,4-diguanidino-phenoxy)-2,4-diguanidino-cyclohexyl [1,1′-biphenyl]-4-ylcarbamate
    166691
    N-[5-(4-guanidino-naphthalen-1-ylamino)-2,4-bis-(4-guanidino-naphthalen-1-yloxy)-cyclohexyl]-guanidine
    166811
    N-[5-guanidino-4-(4-guanidino-naphthalen-1-yloxy)-2-(4-guanidino-phenoxy)-cyclohexyl]-guanidine
    166812
    N-{2-[2,4-diguanidino-5-(4-guanidino-phenoxy)-cyclohexyloxy]-5-guanidino-phenyl}-guanidine
    166829
    5-(2,4-bis(imidazolidin-2-ylideneamino)phenoxy)-2,4-bis(imidazolidin-2-ylideneamino)cyclohexanol
    166829a
    2,4-diamino-5-(2,4-diaminophenoxy)cyclohexanol
    166830
    N1,N3-di(imidazolidin-2-ylidene)-4,6-bis(4 (imidazolidin-2-ylideneamino)phenoxy)cyclohexane-1,3-diamine
    166830a
    4,6-bis (4-aminophenoxy)cyclohexane-1,3-diamine
    1435–6
    (2R)-4-((R)-1-cyclohexyl-3-((S)-2-(((S)-2-(cyclohexylmethyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-2-(cyclohexylmethyl)-1-(2-(4-isobutylphenyl)propyl)piperazine
    TFA
    trifluoroacetic acid
    BSA
    bovine serum albumin
    pERTKR-AMC
    pGlu-Arg-Thr-Lys-Arg-methylcoumarinamide
    PBS
    phosphate-buffered saline
    RIA
    radioimmunoassay.

  • Received December 1, 2011.
  • Accepted December 14, 2011.
  • Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 81 (3)
Molecular Pharmacology
Vol. 81, Issue 3
1 Mar 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of Prohormone Convertases PC1/3 and PC2 by 2,5-Dideoxystreptamine Derivatives
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

PC1/3 and PC2 Inhibitors

Mirella Vivoli, Thomas R. Caulfield, Karina Martínez-Mayorga, Alan T. Johnson, Guan-Sheng Jiao and Iris Lindberg
Molecular Pharmacology March 1, 2012, 81 (3) 440-454; DOI: https://doi.org/10.1124/mol.111.077040

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

PC1/3 and PC2 Inhibitors

Mirella Vivoli, Thomas R. Caulfield, Karina Martínez-Mayorga, Alan T. Johnson, Guan-Sheng Jiao and Iris Lindberg
Molecular Pharmacology March 1, 2012, 81 (3) 440-454; DOI: https://doi.org/10.1124/mol.111.077040
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Effects of Small Molecule Ligands on ACKR3 Receptors
  • Michaelis-Menten Quantification of GPCR-G Protein Signaling
  • Anti-aromatase activity of exemestane phase II metabolites
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics